GlassScriptPhysician profile
John M Corsi
NPI 1689685042
$17,700.64
in general payments reported to CMS, 2019-2025
53 companies · $1,840 in 2025
The $1,840 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,817 · 2020: $2,495 · 2021: $3,781 · 2022: $2,467 · 2023: $2,540 · 2024: $1,761 · 2025: $1,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,140.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,089.95 | 2019-2025 | |
| Abbvie INC. | $2,014.74 | 2019-2025 | Ubrelvy, Synthroid, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,787.60 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,763.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Collegium Pharmaceutical, INC. | $1,464.79 | 2019-2025 | Xtampza |
| Glaxosmithkline, LLC. | $1,175.45 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $1,071.46 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $810.21 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $738.62 | 2019-2024 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $420.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biodelivery Sciences International, INC. | $380.40 | 2020-2021 | |
| Exact Sciences Corporation | $366.82 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $323.48 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $303.74 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $291.84 | 2021-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Corsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.